Clinical Trials on NK-Cell Lymphoma, Unclassifiable

Total 6783 results

National Cancer Institute (NCI)

Completed

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
M.D. Anderson Cancer Center
Leudosite

Terminated

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Lymphoma, B-Cell | Lymphoma, T-Cell | Lymphoma, Low-Grade | Leukemia, Lymphocytic, Acute | Leukemia, Lymphocytic, Chronic

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
GlaxoSmithKline; Novartis

Terminated

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Chronic Lymphocytic Leukemia | B-Cell Non-Hodgkin's Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditions

United States, Canada, Australia, Puerto Rico
University of Colorado, Denver
National Cancer Institute (NCI)

Recruiting

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma

United States
Eureka Therapeutics Inc.
Duke University; Duke Clinical Research Institute

Terminated

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Lymphomas Non-Hodgkin's B-Cell

United States
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)

T Cell Lymphoma | T Cell Prolymphocytic Leukemia | T-cell Acute Lymphoblastic Leukemia | T Cell Leukemia | T-Cell Lymphoma of CNS | T Cell Childhood ALL

China
National Cancer Institute (NCI)

Completed

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Loyola University
Leukemia Research Foundation

Active, not recruiting

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

B-Cell Acute Lymphoblastic Leukemia, Adult | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

United States
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, United Kingdom, Netherlands
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
Aegera Therapeutics
The Leukemia and Lymphoma Society

Terminated

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

Canada, United States
Children's Hospital Medical Center, Cincinnati
Jazz Pharmaceuticals

Completed

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Anaplastic Large Cell Lymphoma | Diffuse Large Cell Lymphoma | Gray Zone Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Lymphoma, B-Cell, Marginal Zone | Leukemia, Lymphoid | Leukemia, Lymphocytic, Chronic, B-Cell

China
University of Pennsylvania

Completed

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

United States
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell Lymphoma

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
University of Miami

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Adult T-cell Leukemia-Lymphoma | ATLL

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

HIV Infection | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular... and other conditions

United States
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

Japan
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Affiliated Hospital of Nantong University

Not yet recruiting

Obinutuzumab in Chinese Real-world Patients With iNHL

Lymphomas Non-Hodgkin's B-Cell

China
Austin Health
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP)

Lymphomas Non-Hodgkin's B-Cell

Australia
Dana-Farber Cancer Institute
AbbVie

Recruiting

Venetoclax Plus Inotuzumab for B-ALL

B-Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | ALL

United States
Kami Maddocks, MD
Pharmacyclics LLC.

Active, not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent... and other conditions

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
David Bond, MD

Completed

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Small Lymphocytic Lymphoma | Richter Syndrome | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell... and other conditions

United States
Vinmec Research Institute of Stem Cell and Gene...
National Institute of Hematology and Blood Transfusion, Vietnam

Recruiting

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

B-Cell Non Hodgkin Lymphoma | B-Cell Acute Lymphoblastic Leukemia

Vietnam
Sidney Kimmel Comprehensive Cancer Center at Johns...
Amgen

Active, not recruiting

A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

Acute Lymphoblastic Leukemia | B-cell Non Hodgkin Lymphoma | Pre B-Cell Acute Lymphoblastic Leukaemia

United States
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Spain, Italy, Austria
International Extranodal Lymphoma Study Group (IELSG)

Completed

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
Ottawa Hospital Research Institute

Unknown

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

B Cell Non-Hodgkin's Lymphoma | B Cell Lymphocytic Leukemia
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

B Cell Lymphoma | B Cell Leukemia

China
Chinese PLA General Hospital

Unknown

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Follicular Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

United States
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma

China
Beam Therapeutics Inc.

Recruiting

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Lymphoblastic Lymphoma | Lymphoblastic Leukemia | T-Cell Lymphoblastic Leukemia/Lymphoma

United States
Spectrum Pharmaceuticals, Inc

Completed

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States

Clinical Trials on NK-Cell Lymphoma, Unclassifiable

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations